PHK
MCRB icon

Point72 Hong Kong’s Seres Therapeutics MCRB Stock Holding History

Point72 Hong Kong’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-357
Closed -$24K – 2205
2022
Q2 		$24K Buy
357
+64
+22% +$5.51K ﹤0.01% 1517
2022
Q1 		$42K Sell
293
-83
-22% -$12.8K ﹤0.01% 1377
2021
Q4 		$63K Buy
+376
New +$59.7K ﹤0.01% 1286
2021
Q3 		– Sell
-252
Closed -$120K – 2259
2021
Q2 		$120K Buy
252
+34
+16% +$14.3K ﹤0.01% 1277
2021
Q1 		$90K Buy
218
+28
+15% +$12.9K ﹤0.01% 1175
2020
Q4 		$93K Buy
+190
New +$111K ﹤0.01% 1080
2020
Q3 		– Sell
-28
Closed -$3K – 1387
2020
Q2 		$3K Buy
+28
New +$2.46K ﹤0.01% 1058

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Point72 Hong Kong's MCRB Position: Q3 2022 in Review

Point72 Hong Kong sold out of Seres Therapeutics (MCRB) in Q3 2022, closing a stake of 357 shares — an estimated $24K sold.

Point72 Hong Kong first reported a position in MCRB in Q2 2020 and held it in 7 quarters. The position peaked at $120K in Q2 2021. 119 funds tracked by Wall St. Rank hold MCRB as of Q3 2022.

  • Point72 Hong Kong reported no remaining Seres Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 357 Seres Therapeutics shares in Q3 2022, an estimated $24K.
  • Point72 Hong Kong first reported a position in Seres Therapeutics in Q2 2020 and held it in 7 quarters.
  • Point72 Hong Kong's Seres Therapeutics position peaked at $120K in Q2 2021.
  • 119 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2022.

Based on Point72 Hong Kong's 13F filing for Q3 2022, filed 14 Nov 2022.